Asia’s largest integrated insulin manufacturing and R&D facility
Biocon brings many significant advantages to healthcare in Malaysia through a strategic partnership with Duopharma Biotech Berhad, Malaysia’s leading pharmaceutical company. The partnership is leveraging its innovativeness and ingenuity to open up a world of possibilities for healthcare professionals and patients. Patient outcomes are improving with affordable cancer and insulin therapies. Biocon’s subsidiary – Biocon Sdn Bhd – and Duopharma Marketing Sdn Bhd boosted the supply of locally produced Insugen (recombinant human insulin). The successful launch of Basalog One (Insulin Glargine pen) as well as Zuhera (Trastuzumab) replaced the fear of disease with the hope of a better life.